Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Key growth drivers accelerating in the US, while market still
recovering from COVID-19
COVID-19 continues to weigh on
US Oncology market
Biopsy rates remain suppressed (%)
- Breast
Melanoma
Lung
Q2 showing partial recovery in US with growth drivers
and recent launches accelerating
USD m, % cc
Launches1
Growth drivers²
120
115
110
105
100
95
90
85
80
75
70
65
60
55
50
45
Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr
+10%
vs. PY
Pre-
COVID
133
120
■ Growth drivers and launches contribute
49% of sales (up from 47% Q1 2021)
☐
◉
PromactaⓇ USD 235m in Q2, +7% QoQ
KisqaliⓇ USD 83m in Q2, +17% QoQ
TafinlarⓇ+MekinistⓇ USD 151m in Q2,
+8% QoQ
Piqray®, TabrectaⓇ and AdakveoⓇ
together USD 133m in Q2, +11% QoQ
584
616
☐
Q1 2021
Q2 2021
1. Launches include Piqray®, AdakveoⓇ and TabrectaⓇ 2. Growth drivers include PromactaⓇ/Revolade®, TafinlarⓇ+ MekinistⓇ, KisqaliⓇ, LutatheraⓇ, KymriahⓇ
27 Investor Relations | Q2 2021 Results
1 NOVARTIS | Reimagining MedicineView entire presentation